Horisont 2020 Ühiskonnaprobeem 1:
|
|
|
- Margery Holt
- 6 years ago
- Views:
Transcription
1 Horisont 2020 Ühiskonnaprobeem 1: Tervishoid, demograafilised muutused ja heaolu Argo Soon konsultant Eesti Teadusagentuur Horisont 2020: Ühiskonnaprobleem 1 Märksõnad: personaalmeditsiin haruldased haigused bio-monitooring vaimne tervis võrdlev tõhususe uuring nutikad tehnoloogiad e- ja m-tervis robootika patsiendi kaasamine aktiivse ja tervena vananemine andmeturve suurandmed väärindamine AMR infektsioonhaigused ema ja lapse tervis hõbemajandus silver economy Horisont 2020: SC1 konkursid Tööprogramm 2 aastaks : Osa teemasid avatud vaid 2016 Osa teemasid avatud vaid 2017 Osa teemasid avatud 2016 ja 2017 Taotlemisprotseduur 2016 vaid ühe-astmeline taotlemine teemat kahe-astmelise taotlusprotseduuriga 1
2 Horisont 2020: Taotlusprotseduur 1-astmeline: kogu taotlus korraga 2-astmeline: I aste: Taotluse lühivorm Ca 10 lk Tehnilise teostamise osa pole vaja, Vaid teaduslik ekstsellentsus ja mõju II aste: Täismahus taotlus Vaid siis, kui I astme taotlus edukas Lk arv/maht kirjas konkreetses juhendis Horisont 2020: Projektitüübid Peamised projektitüübid: Research and innovation action Research and innovation action 100% Innovation action Innovation action 70% Coordination and support action SME-instrument; incl. fast track to innovation Pre-commercial procurement co-fund actions Public procurement of innovative solutions ERA-Net co-fund Joint programming 20SC1-Health% _pre-pub.pdf 2
3 Horisont 2020: Ühiskonnaprobleem 1 Võrreldes 7RP-ga: Teemad laiemad Rohkem vabadust interpreteerimiseks Reeglid (eriti rahastusreeglid) lihtsamad Nt: üks projekt üks määr kõigil partnereil Konkurss aga suurem edukusmäär 10-20% sõltub teemast 4 tehnilist jaotust Personaalmeditsiin PHC Research and innovation action Innovation action Koordineerivad ja toetavad tegevused HCO Networking, no research VKE instrumendi teemad Muud tegevused Sisuline struktuur: 1.1 Baasuuringud tervise ja haiguse mõistmiseks 1.2 Haiguste ennetamine 1.3 Haiguste ravi 1.4 Aktiivsena vananemine ja eakate eneseabi 1.5 Metoodika ja andmed 1.6 Tervishoiusüsteemid 3
4 1.1UNDERSTANDING Märksõnad: HEALTH, WELL-BEING AND DISEASE SC1-PM : Multi omics for personalised therapies addressing diseases of the immune system SC1-PM : New concepts in patient stratification SC1-PM : Diagnostic characterisation of rare diseases SC1-PM : Networking and optimising the use of population and patient cohorts at EU level 1.2. Märksõnad: PREVENTING DISEASE SC1-PM : The European Human Biomonitoring Initiative SC1-PM : Vaccine development for malaria and/or neglected infectious diseases SC1-PM : Promoting mental health and well-being in the young Märksõnad: 1.3 TREATING AND MANAGING DISEASES SC1-PM : New therapies for rare diseases SC1-PM : New therapies for chronic diseases SC1-PM : Comparing the effectiveness of existing healthcare interventions in the adult population SC1-PM : Clinical research on regenerative medicine 4
5 1.4 Märksõnad: ACTIVE AGEING AND SELF-MANAGEMENT OF HEALTH SC1-PM : PCP - ehealth innovation in empowering the patient SC1-PM : PPI for deployment and scaling up of ICT solutions for active and healthy ageing SC1-PM : EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities SC1-PM : Personalised coaching for well-being and care of people as they age 1.5 Märksõnad: METHODS AND DATA SC1-PM : In-silico trials for developing and assessing biomedical products SC1-PM : Personalised computer models and in-silico systems for well-being SC1-PM : Big Data supporting Public Health policies SC1-PM : PPI for uptake of standards for the exchange of digitalised healthcare records SC1-PM : Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector 1.6 HEALTH CARE PROVISION AND INTEGRATED CARE SC1-PM : Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries 5
6 Horizon 2020: WP Health Description of a topic Horisont 2020 ühiskonnaprobleem 1 Kaks eraldi programmi Innovative Medicines Initiative IMI2 Public-Private Partnership EFPIA-European Commission European & Developing Countries Clinical Trial Partnership EDCTP2 HIV, malaria, neclected infections Public-Public Partnership Euroopa Komisjon, Osalevad EL riigid, Aafrika riigid Horisont 2020 ühiskonnaprobleem 1 Tervise temaatika ka teistes valdkondades: SC2: Food security, sustainable agriculture, forestry SC3: Secure, clean and efficient energy SC5: Climate action, resource efficiency raw materials Industrial Leadership topics: ICT Nanotechnologies Advanced materials Biotechnology Space 6
7 H2020 Ühiskonnaprobleem 1 tähtajad Taotlusvooru avanemine: 2015 oktoobri keskpaik Taotuse esitamise tähtajad: alates jaanuarist 2016 Horizon 2020: Additional information Horizon 2020 web-page Draft programmes for Horizont 2020 Participant Portal Horizon 2020 help-desk 7
8 Horisont 2020 tugi Eestis Eesti Teadusagentuur konsultant: 8
State of play and outlook
Health in Horizon 2020 State of play and outlook European High level meeting Madrid, 2 nd October 2012 Didier Gambier, Head of the Horizontal Aspects Unit, Health Directorate Directorate-General for European
Personalised medicine. Promoting healthy ageing. Human biomonitoring. Health ICT. Infectious Diseases. Maternal and child health
SC1 - Health SC1 - Main research priorities for 2016-2017 Personalised medicine Promoting healthy ageing Human biomonitoring Health ICT Infectious Diseases Maternal and child health Personalised medicine
Personalised Medicine in Horizon 2020 Opportunities for biotechnology companies
Personalised Medicine in Horizon 2020 Opportunities for biotechnology companies Entrepreneurial Discovery Focus Group on biotechnology, North-East Region, Iași, Romania, 6.06.2016 Alexandru COSTESCU Innovative
EU health research policies in the FP7 and Horizon Dr Ruxandra Draghia-Akli Director for Health European Commission
EU health research policies in the FP7 and Horizon 2020 Dr Ruxandra Draghia-Akli Director for Health European Commission International Symposium 'the future of translational medical research: the role
EU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
Oportunidades de financiamento H2020 Desafio Societal 1 Saúde, alterações demográficas e bem-estar Patrícia Calado, NCP Saúde
Gabinete de Promoção dos Programa Quadro ID&I Oportunidades de financiamento H2020 Desafio Societal 1 Saúde, alterações demográficas e bem-estar Patrícia Calado, NCP Saúde OBJECTIVOS DO H2020 NA ÁREA DA
Opportunities for African Participation in H2020. Tentative Work Programme
Opportunities for African Participation in H2020 Tentative Work Programme 2016-2017 caast-net-plus.org CAAST-Net Plus is funded by the European Union s Seventh Framework Programme for Research and Technological
Horizon 2020 Review of Work Programme Focus on topics including Clinical Trials/Studies
Horizon 2020 Review of Work Programme 2018 2020 Focus on topics including Clinical Trials/Studies ECRIN European Correspondent Meeting Dr Sabine Klager - 08/11/2017 Health, demographic change and wellbeing
Horizon 2020 Societal Challenges
Capacity building and international networking NCP Meeting 6 May 2014, Montevideo Uruguay Horizon 2020 Societal Challenges Flavia Mariani, IRD Giorgos Tzamtzis, FORTH/PRAXI Overview of the Societal Challenges
NMBP calls in Leadership in Enabling and Industrial Technologies Work Programme Information Day LEIT & FET Bratislava, 9 September 2014
NMBP calls in 2015 Leadership in Enabling and Industrial Technologies Work Programme 2014-15 Information Day LEIT & FET Bratislava, 9 September 2014 José-Lorenzo Vallés DG Research and Horizon 2020: Key
The International Consortium for Personalised Medicine
The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals
Societal Challenges ICT Energy Climate Change
Societal Challenges ICT Energy Climate Change Capacity building and International Networking 5-6 May 2014 Montevideo Uruguay Giorgos Tzamtzis International Cooperation Unit Praxi Network Horizon 2020:
Innovation in medical devices as response to Europe's healthcare challenges. Industry's viewpoint
HIGH-LEVEL CONFERENCE "EXPLORING INNOVATIVE HEALTHCARE THE ROLE OF MEDICAL TECHNOLOGY INNOVATION AND REGULATION" Innovation in medical devices as response to Europe's healthcare challenges Industry's viewpoint
Participation in Horizon 2020 and the new Work Programme on the 3 SCs
State of Affairs and Future of the EU-EaP STI Cooperation Brussels, 3 September 2015 Participation in Horizon 2020 and the new Work Programme on the 3 SCs Zygmunt Krasiński IPPT PAN, Poland IncoNet EaP
Funding opportunities for Health and Biotech from the EU Research and Innovation program Horizon 2020 Medtec, 04. April 2017, Stuttgart
Funding opportunities for Health and Biotech from the EU Research and Innovation program Horizon 2020 Medtec, 04. April 2017, Stuttgart Dr. Lydia Kammler www.nks-lebenswissenschaften.de Horizon 2020 2014-2020
KPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
Horizon H2020 Training for TECPAR Opportunities to participate in European Research Projects
Horizon 2020 H2020 Training for TECPAR Opportunities to participate in European Research Projects 1 2 Europa 2020 Strategy for a smart, sustainable and inclusive growth Innovation Union Horizon 2020 Flagship
New Horizons for TB Vaccine Research
New Horizons for TB Vaccine Research IJmuiden, 10 February 2015 Line MATTHIESSEN, MD, PhD Head of Unit - 'Fighting infectious diseases and global epidemics, Health Directorate Directorate-General for Research
Grantové příležitosti pro oblast zdraví
Grantové příležitosti pro oblast zdraví Informační den oblasti ZDRAVÍ 18.5. 2016 Eva Sebronova, sebronova@tc.cz Hodnotící zpráva EK 7. RP http://ec.europa.eu/research/participants/portal/desktop/en/funding/reference_docs.html#h2
Science, Demographic Change and Wellbeing in Horizon 2020
Science, Demographic Change and Wellbeing in Horizon 2020 "L Europa e la Salute: le politiche sanitarie e le diseguaglianze sociali in sanità", Regione Basilicata Matera, 28 maggio 2014 Rosanna D'Amario
Personalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
Regulatory Support to EU Research
Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific
Rare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
Webinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease
Webinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease 09.07.2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction Iwona Jablonska,
Webinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
The Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA?
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA? Jesús M. Hernández Rivas Instituto de Investigación Biomédica de Salamanca. Universidad de Salamanca. Servicio de Hematología. Hospital Universitario de Salamanca.
Information Day Leeds, UK 27 October 2015 Treating and managing disease
The societal challenge 'Health, demographic change and well-being' Work programme 2016-2017 Information Day Leeds, UK 27 October 2015 Treating and managing disease Image credit: Adam Fagen Rallying for
Public private partnerships in support to regulatory sciences
Public private partnerships in support to regulatory sciences The Innovative Medicines Initiative example M. Chlebus 3 October 2017 www.efpia.eu Summary: Partnering on regulatory sciences Progress much
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
Innovative Medicines Initiative - the story so far
Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European
Making the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
Horizon Scanning: future skills and competences of the health workforce in Europe. (draft findings)
Horizon Scanning: future skills and competences of the health workforce in Europe (draft findings) MATT EDWARDS and JOHN FELLOWS WP6, EU JA on Health Workforce Planning and Forecasting Centre for Workforce
ABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
University of Manchester and EU Funding Health & Social Care
University of Manchester and EU Funding Health & Social Care 1. FP7 Overview Facts and Figures 2. Horizon 2020 Story So Far 3. Future Activities Horizon 2020 and Beyond Claire Faichnie and Liz Fay EU Funding
Public-Private Partnerships in FP7 and in Horizon 2020
Public-Private Partnerships in FP7 and in Horizon 2020 Andrea GENTILI Industrial Technologies DG Research and Innovation Brussels, 27 June 2013 Horizon 2020: Key elements Three pillars: societal challenges,
FP7 Cooperation Work Programme: Health-2011 Topics and contact points
FP7 Cooperation Work Programme: Health-2011 Topics and contact points Date of publication: 30 July 2010 Call identifiers: Indicative budgets Deadlines FP7-HEALTH-2011-single-stage EUR 160.5 million 10
Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017
FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures
Centre for NanoHealth
Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine Unique interdisciplinary R&D environment,
Innovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium
Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes
The Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
The Seventh Framework Programme ( )
The Seventh Framework Programme (2007-2013) Opportunities for Cardiovascular Research 1 Octavi Quintana Trias, MD, MPH Director Health DG Research - European Commission Octavi.Quintana-Trias@ec.europa.eu
Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
Topic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
Horizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.
Horizon 2020 funding opportunities for Regenerative Medicine (2018-2020) Rudolf Fryček, PhD. Disclaimer: Any information mentioned is preliminary only, always consult the official documents. 1 Outline
Introduction to Horizon 2020
Introduction to Horizon 2020 20.05.2015 Michaela Pöter Management Jülich Content 1. Horizon 2020: Structure and Key Objectives 2. Priority I: Excellent Science 3. Priority II: Industrial Leadership 4.
Recent Trends in Companion Diagnostic Test Development Partnerships
Recent Trends in Companion Diagnostic Test Development Partnerships Andrew S. Thompson, PhD, Director of Therapy and Analysis, GlobalData Medical, London Tyler Fletcher, Global Head, GlobalData Medical,
EMA Support to Innovation: Operation of the EU Innovation Network
EMA Support to Innovation: Operation of the EU Innovation Network 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Marisa Papaluca
Horizon 2020 Health Summit-IIS La Fe. Valencia, 12 de diciembre de 2017
Horizon 2020 Health Summit-IIS La Fe Valencia, 12 de diciembre de 2017 2 History 3 AsphaTeam +75 members Consultants with Life Science Background 20 team members with PhD High knowhow in drug development
Making the entire pharmaceutical chain sustainable. Bengt Mattson. Policy Manager, LIF (Manager,CSR & Environmental Affairs, Pfizer AB)
Making the entire pharmaceutical chain sustainable Bengt Mattson Policy Manager, LIF (Manager,CSR & Environmental Affairs, Pfizer AB) www.ansvarsblogg.se Twitter: CSRBengt LIF, Feb 15, 2017 Sustainability
Horizon 2020 Call Fiche 2014: Food Security*
Horizon 00 Call Fiche 014: Food Security* * Food security, sustainable agriculture forestry, marine maritime inl water research the bioeconomy Funding Availabilities Budget for the Food activity 014-00:
Nanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
Explaining EDCTP2 and its perspective on Capacity Building for PV of products used in managing PRDs
Explaining EDCTP2 and its perspective on Capacity Building for PV of products used in managing PRDs 16 th Annual meeting of the International Society of Pharmacovigilance Jean Marie Vianney Habarugira,
http://www.healthncpnet.eu What are we going to talk about? International Cooperation in the FP7 Health 2013 Call International Cooperation in the FP7 KBBE 2013 Call How to find a partner? (Support Services
Horizon 2020 biodiversity-relevant projects and calls + Outlook to Horizon Europe
Horizon 2020 biodiversity-relevant projects and calls + Outlook to Horizon Europe European Commission DG Research and Innovation Marco Fritz marco.fritz@ec.europa.eu CGBN meeting 18/09/18, Brussels All
Personalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
ENVIRONMENT, PUBLIC HEALTH AND FOOD SAFETY (ENVI) Personalised Medicine - Current Status KEY FINDINGS
Briefing ENVIRONMENT, PUBLIC HEALTH AND FOOD SAFETY (ENVI) Personalised Medicine - Current Status KEY FINDINGS Personalised Medicine has the potential to significantly contribute to a better and more sustainable
Investing in Research, Development and Innovation for Global Health
The Malaria Advocacy Working Group (MAWG) of the Roll Back Malaria Partnership s (RBM) contribution to the European Commission consultation on the Green Paper - From Challenges to Opportunities: Towards
- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
A bold vision for 2025
Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Annual Stanford Medicine Population Health Sciences Colloquium October 26, 2015
Industrial Technology in Horizon KETs and PPPs - SPIRE. Søren Bøwadt DG Research and Innovation Directorate Industrial Technologies
Industrial Technology in Horizon 2020 - KETs and PPPs - SPIRE Søren Bøwadt DG Research and Innovation Directorate Industrial Technologies Horizon 2020: Key elements A single programme with three pillars:
E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
Possibilities for wind energy projects in the Horizon 2020 programme
HORIZON HORIZON 2020 2020 Possibilities for wind energy projects in the Horizon 2020 programme Matthijs SOEDE Research Programme Officer Unit K3 New and Renewable Energy Sources DG Research and Innovation
EU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
EU Research and Innovation in support to chemical safety
EU Research and in support to chemical safety ECHA topical workshop, Helsinki, 19 April 2016 Research and Dr Christian Desaintes DG RTD Health Chemical legislation and activities in the EC Research Framework
THE EU FRAMEWORK PROGRAMME FOR RESEARCH AND INNOVATION HORIZON H Energy Calls
THE EU FRAMEWORK PROGRAMME FOR RESEARCH AND INNOVATION HORIZON 2020 H2020 - Energy Calls 2016 2017 Lisa.lundmark@energimyndigheten.se HORIZON 2020 Horizon 2020 Overall Objectives Responding to the economic
HORIZON The importance of and opportunities for private sector involvement in European R&D. Patrik Kolar
HORIZON 2020 The importance of opportunities for private sector involvement in European R&D Patrik Kolar European Commission DG Research Innovation Directorate F "Bioeconomy" Head of unit F3: Agri-Food
The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
Opportunities for Vaccine Research in Horizon 2020
Opportunities for Vaccine Research in Horizon 2020 Workshop on the joint procurement of medical countermeasures 29 April 2015 Luxemburg Cornelius Schmaltz, MD European Commission DG Research and Innovation
Building the Europe of Knowledge
Building the Europe of Knowledge 7 th Framework Programme 2007-2013 Nanotechnology! All information preliminary! FP7 1. Capacities: Infrastructures 2. People: Erasmus, Marie-Curie 3. Ideas: ERC 4. Cooperation:
Promoting collaboration: Strategies and programs within health research and innovation
Promoting collaboration: Strategies and programs within health research and innovation Anne K Fahlvik, PhD, Executive director Mari K Nes, PhD, Special Adviser The Research Council of Norway The Research
European Research Funding. HORIZON 2020 observations and tips
European Research Funding HORIZON 2020 observations and tips Paul Knobbs European Funding Manager Research Support Office Aston University I ll start with a few tips. Become an expert reviewer. DO IT.
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT
ERNs and Research - State of play from the European Commission perspective
ERNs and Research - State of play from the European Commission perspective Iiro Eerola Scientific Project Officer Innovative and Personalised Medicine Unit Directorate Health DG Research & Innovation European
The Importance of Modern Biotechnology in Job Creation in Ireland
The Importance of Modern Biotechnology in Job Creation in Ireland Dr. Michael Gillen, Director Irish BioIndustry Association & Senior Executive, Pharmachemical Ireland Europe 2020 Objective is to address
"EU-funding of Microbiome research under FP7 and H2020"
Personalised nutrition for better health - Targeting the Microbiome Session 1: Personalised nutrition for better health: realising the potential "EU-funding of Microbiome research under FP7 and H2020"
EU Regulation Review: challenges and opportunities for industry
EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general
Innovative Medicines Initiative:
Innovative Medicines Initiative: Opportunities for local players to become important parts of multicountry pharma innovation Nathalie Serigneuret 4 March 2015 Clinical Trials Conference 2015, Budapest
Royal Society of Chemistry Response to the House of Commons Science and Technology Committee Call For Evidence: Antimicrobial Resistance
Royal Society of Chemistry Response to the House of Commons Science and Technology Committee Call For Evidence: Antimicrobial Resistance The Royal Society of Chemistry is the world s leading chemistry
European Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
SMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project? IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
Neurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
Societal Challenges SOCIETAL CHALLENGES. H2020 General Training
4/12/17 TURKEY IN HORIZON 2020 ALTUN/HORIZ/TR2012/0740.14-2/SER/005 H2020 General Training Societal Challenges SOCIETAL CHALLENGES H2020 reflects the policy priorities of the Europe 2020 strategy and addresses
Diagnostics gathering intelligence to fight antimicrobial resistance
Diagnostics gathering intelligence to fight antimicrobial resistance Arjon van Hengel European Commission DG Research and Innovation, Health Directorate Unit "Fighting Infectious Diseases and Advancing
Research & Innovation in food, health and ageing
Research & Innovation in food, health and ageing Feasibility study on dietary recommendations for older adults in the European Union 23-24 October 2014 Ispra, IT Isabelle de Froidmont-Görtz European Commission
EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008
Work plan for 2008 1 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2 The ETP is
Personalised medicine towards the market and patients: the approval process
An agency of the European Union Personalised medicine towards the market and patients: the approval process European Medicines Agency s perspective Presented by: Marisa Papaluca Amati Human Medicines Development
EMA Regulatory Science to 2025
23 October 2018 EMA/723198/2018 Scientific Committees Regulatory Science Strategy EMA Regulatory Science to 2025 Reference documents Reference material 30 Churchill Place Canary Wharf London E14 5EU United
Les opportunités dans le domaine de la santé
Horizon-2020 appels 2018 Les opportunités dans le domaine de la santé Les slides seront disponibles sur le site web du NCP-Wallonie Emilie ETOUNDI ! Versions provisoires et non officiellement adoptées
Europe, a world leader in Nanotechnologies, Biomaterials and Micro-Nano-Electronics for Healthcare
Europe, a world leader in Nanotechnologies, Biomaterials and Micro-Nano-Electronics for Healthcare Nicolas Gouze, General Secretary of ETP Nanomedicine Trends & paradigmshifts in Healthcare Demographic
Research and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
Sustainable Health Care Systems: Research and Innovation
Backgroundpaper B7-Communiqué Sustainable Health Care Systems: Research and Innovation Version II BDI, BUSINESSEUROPE Canadian Chamber of Commerce CBI CONFIDUSTRIA Keidanren MEDEF US Chamber of Commerce
REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research
REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research Charles Kessler European Commission DG Research, Health Directorate Outline of presentation Main features of
Australian Medical Research and Innovation Priorities Determination 2018
Australian Medical Research and Innovation Priorities 2018 2020 Determination 2018 I, Ian Frazer, Chair of the Australian Medical Research Advisory Board, make the following instrument on behalf of the
Vaccine Clinical Trials
Vaccine Clinical Trials Simon Agwale, PhD CEO Innovative Biotech Ltd, Keffi, Nigeria Chair, Developing countries Coordinating Committee (DCCC)-European and Developing Countries Clinical Trials Partnership
Public private partnerships to encourage patient access
Public private partnerships to encourage patient access 5 th SFE SFUS Conference Challenges for efficient health care in Central and Eastern Europe Belgrade, 10 th October 2015 How does IMI work? The Innovative
Horizon 2020 / INNOSUP
09/11/2016 Horizon 2020 / INNOSUP-1-2015 Topic Cluster facilitated projects for new value chains Aims Development of new cross-sectoral industrial value chains across the EU by building upon the innovation
Energy / Environment NCP Sophie LOQUEN ADEME 14th November 2016
1 Energy / Environment NCP Sophie LOQUEN ADEME 14th November 2016 1 Main policy elements 1 2030 Framework for Climate and Energy 1 Energy Union 1 Energy Union 5th pillar (R,I & C) 1 Winter package 1 Energy